These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 23881922)

  • 1. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma.
    Fisel P; Stühler V; Bedke J; Winter S; Rausch S; Hennenlotter J; Nies AT; Stenzl A; Scharpf M; Fend F; Kruck S; Schwab M; Schaeffeler E
    Oncotarget; 2015 Oct; 6(31):30615-27. PubMed ID: 26384346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
    Kim Y; Choi JW; Lee JH; Kim YS
    Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
    Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
    Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
    J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
    Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 8. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
    Du P; Ye L; Yang Y; Jiang WG
    Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
    Choi JW; Lee JH; Park HS; Kim YS
    J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic alterations of Krüppel-like factor 4 and its tumor suppressor function in renal cell carcinoma.
    Li H; Wang J; Xiao W; Xia D; Lang B; Yu G; Guo X; Guan W; Wang Z; Hu Z; Liu J; Ye Z; Xu H
    Carcinogenesis; 2013 Oct; 34(10):2262-70. PubMed ID: 23722653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
    Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
    PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
    Gotanda Y; Akagi Y; Kawahara A; Kinugasa T; Yoshida T; Ryu Y; Shiratsuchi I; Kage M; Shirouzu K
    Anticancer Res; 2013 Jul; 33(7):2941-7. PubMed ID: 23780984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
    White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
    Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
    Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
    Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
    Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
    BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.